Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: significance of guidelines developed for each underlying disease.
{"title":"Clinical practice guidelines for management of disseminated intravascular coagulation in Japan 2024: significance of guidelines developed for each underlying disease.","authors":"Hidesaku Asakura","doi":"10.1007/s12185-025-03928-y","DOIUrl":null,"url":null,"abstract":"<p><p>Disseminated intravascular coagulation (DIC) is a severe condition characterized by systemic, persistent activation of coagulation in the presence of an underlying disease, leading to the formation of microthrombi in small blood vessels. In DIC, fibrinolysis is also activated alongside coagulation, but the extent of fibrinolysis varies significantly depending on the underlying condition. The classification of DIC types is crucial not only for understanding the pathophysiology involved, but also for selecting appropriate treatment strategies. Internationally, DIC is often associated with sepsis, typically presenting with ischemic organ damage. However, it is important to recognize that some forms of DIC exhibit minimal ischemic organ damage but severe bleeding symptoms. When diagnosing and treating DIC, considering the underlying condition and disease type can lead to better clinical outcomes. This underscores the need for DIC management guidelines that are based on an understanding of the underlying disease. The newly released \"Clinical Practice Guidelines for Management of Disseminated Intravascular Coagulation in Japan 2024\" offer the first comprehensive guidelines for detailed management based on specific underlying conditions, providing a groundbreaking contribution to the global DIC clinical community.</p>","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12185-025-03928-y","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Disseminated intravascular coagulation (DIC) is a severe condition characterized by systemic, persistent activation of coagulation in the presence of an underlying disease, leading to the formation of microthrombi in small blood vessels. In DIC, fibrinolysis is also activated alongside coagulation, but the extent of fibrinolysis varies significantly depending on the underlying condition. The classification of DIC types is crucial not only for understanding the pathophysiology involved, but also for selecting appropriate treatment strategies. Internationally, DIC is often associated with sepsis, typically presenting with ischemic organ damage. However, it is important to recognize that some forms of DIC exhibit minimal ischemic organ damage but severe bleeding symptoms. When diagnosing and treating DIC, considering the underlying condition and disease type can lead to better clinical outcomes. This underscores the need for DIC management guidelines that are based on an understanding of the underlying disease. The newly released "Clinical Practice Guidelines for Management of Disseminated Intravascular Coagulation in Japan 2024" offer the first comprehensive guidelines for detailed management based on specific underlying conditions, providing a groundbreaking contribution to the global DIC clinical community.
期刊介绍:
The International Journal of Hematology, the official journal of the Japanese Society of Hematology, has a long history of publishing leading research in hematology. The journal comprises articles that contribute to progress in research not only in basic hematology but also in clinical hematology, aiming to cover all aspects of this field, namely, erythrocytes, leukocytes and hematopoiesis, hemostasis, thrombosis and vascular biology, hematological malignancies, transplantation, and cell therapy. The expanded [Progress in Hematology] section integrates such relevant fields as the cell biology of stem cells and cancer cells, and clinical research in inflammation, cancer, and thrombosis. Reports on results of clinical trials are also included, thus contributing to the aim of fostering communication among researchers in the growing field of modern hematology. The journal provides the best of up-to-date information on modern hematology, presenting readers with high-impact, original work focusing on pivotal issues.